Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3339 - Genetic aberrations driving MET deregulation detected with anchored multiplex PCR and next-generation sequencing

Date

10 Oct 2016

Session

Poster display

Presenters

Brian Kudlow

Citation

Annals of Oncology (2016) 27 (6): 401-406. 10.1093/annonc/mdw380

Authors

B. Kudlow1, J.D. Haimes1, M. Bessette1, N. Manoj1, L. Griffin1, D. Murphy2, R. Shoemaker2, J.W. Myers1, J. Stahl1

Author affiliations

  • 1 Research And Development, ArcherDX, Inc., 80301 - Boulder/US
  • 2 Diagnostics, Ignyta, Inc., 92121 - San Diego/US
More

Resources

Abstract 3339

Background

Deregulation of the receptor tyrosine kinase, MET, is associated with aggressive phenotypes in a variety of human cancers, promoting proliferation, invasive growth and angiogenesis. Several types of genetic aberrations can drive MET deregulation, including gene amplification, overexpression, single nucleotide variants (SNVs), exon 14 skipping and fusions. MET is a target of intensive drug development efforts, however the various mutated forms of MET exhibit unique drug sensitivities. Therefore, detection of these mutations has the potential to guide treatments for cancers driven by MET deregulation. Next-generation sequencing (NGS) enables comprehensive detection of all mutation types from whole genomes and transcriptomes. However, low detection sensitivity, high input requirement and high costs render these approaches impractical for routine detection of mutations from low-input clinical sample types. Anchored Multiplex PCR (AMP™) is a target enrichment strategy for NGS that, by its scalable and quantitative nature, is well suited for detection of each of the modes deregulation of MET.

Methods

We developed AMP-based VariantPlex™ and FusionPlex™ library preparation assays for NGS to detect mutations from DNA and RNA, respectively. We designed AMP probes covering the MET gene to detect copy numbers and SNVs from DNA, and fusions, exon skipping and expression levels from RNA.

Results

VariantPlex and FusionPlex kits enabled detection of MET amplifications, confirmed by FISH, and the resulting overexpression in FFPE samples. Exon 14 skipping was also detected and confirmed by RT-PCR in FFPE and in cells, with concomitant splice site mutations. Lastly, a GTF2I:MET gene fusion and a Y1253D activating point mutation were detected.

Conclusions

These results show that AMP enables comprehensive and sensitive NGS-based detection of multiple mutation types from low-input clinical sample types.

Clinical trial identification

Legal entity responsible for the study

ArcherDX, Inc.

Funding

ArcherDX, Inc.

Disclosure

B. Kudlow, J.D. Haimes, M. Bessette, N. Manoj, L. Griffin, J. Stahl: Full-time employee at ArcherDX, Inc.

D. Murphy: Full-time employee for Ignyta, Inc. R. Shoemaker: Full-time employee at Ignyta, Inc.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings